DORAL, Florida, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields; medical devices; and research and development, today shares it has initiated the up-listing process through the OTCQB in anticipation of approval of its Form 10 Registration Statement.

As planned, the Company has commenced the up-listing process while its Form 10 Registration Statement undergoes approval through the Security and Exchange Commission (SEC). When the SEC declares the Company’s Form 10 registration statement effective, ETST will be a fully reporting company under the Securities Exchange Act of 1934, as amended.

Becoming an OTCQB fully reporting company will increase Earth Science Tech’s value, visibility and transparency, allowing more brokerage firms to trade in the open markets.

“We decided to initiate the up-listing process in anticipation of approval of our Form 10 Registration Statement, so the up-listing process would be partially completed when ETST achieves fully reporting status and would be finalized shortly after. We are very excited to be on the cusp of achieving OTCQB fully reporting status. Once ETST is an OTCQB fully reporting company, we will attract many new investors while keeping current shareholders pleased with our progress. We can now communicate with large-net-worth investors to acquire the needed funds to strengthen our High Grade Full Spectrum Cannabinoids line, KannaBidioiD line and MSN-2 medical device and to exponentially increase our revenues overall,” states Earth Science Tech President, Director and Chairman Nickolas S. Tabraue. “We will also be able to acquire funds to allocate to our CBD generic pharmaceuticals and three IP CBD formulas to progress in our R&D efforts, further increasing company value. We currently have a few potential investors that are now willing to invest, and we have a lot of exciting updates we plan on sharing soon. I greatly appreciate all of our loyal investors.”

About Earth Science Tech, Inc. (ETST)

Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality high-grade full spectrum cannabinoid oil on the market. There are positive results in studies on breast cancer and immune cells through the University of Central Oklahoma; in addition to studies through DV Biologics that prove the Company’s CBD oil formulation lowers cortisol and functions as a neuro-protectant, with positive result case studies through key health organizations. ETST formulates, markets and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD on the market.
To learn more, please visit:

ETST currently has four wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

Earth Science Pharmaceutical

Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharma, Inc. ("ESP"), which is committed to the development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. ESP's CEO and chief science officer, Dr. Michel Aubé, is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. ESP is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
To learn more please visit:

Cannabis Therapeutics

Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds three provisional application patents for a CBD product that is focused on developing treatments for breast and ovarian cancers, as well as two generic CBD based pharmaceutical drugs.
To learn more please visit:


KannaBidioid, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioiD, Inc. (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.
To learn more please visit:

Earth Science Foundation, Inc.

Earth Science Foundation, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Earth Science Foundation, Inc. ("ESF"), is in the process of becoming a nonprofit organization to accept grants and donations to conduct further studies and help donate Earth Science Tech, Inc's effective CBD products to those in need.
To learn more please visit:

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:
Dave Demarest
305.546.7640 Office

Company Contact:
Nickolas S. Tabraue
President, Director, & Chairman